Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke
Key facts
- Where
- Richmond, CanadaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in Canada
- Dongzhimen Hospital, Beijing University of Chinese MedicineRichmond, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dongzhimen Hospital, Beijing
- Trial code
- NCT07163702
- Record updated
- 9 September 2025
- Original description
This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.Read full original descriptionShow less
Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke (EXACT): a Multi-center, Randomized, Double-blinded, Dose-exploration Ⅱa Trial
This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.
Inclusion: Inpatients diagnosed with acute ischemic stroke; Meet the criteria of TCM phlegm-heat and fu-organ excess syndrome; Acute ischemic stroke within 7 days after onset; 6 ≤ NIHSS <20; Aged 18-70 years, male or female; The patient or representative has signed informed consent.
Exclusion: Received or planned thrombolysis or endovascular therapy after onset; Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc; Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 ); With cancers or uncontrolled diabetes; Patients who have used other traditional Chinese medicine for treating acute ischemic stroke since stroke onset; Patients with severe mental disorders, dementia, or other comorbid diseases that may affect neurological function examination; With a history of alcohol or drug abuse or drug dependence; Those known to be allergic to the investigated drug or its components; Known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase > 2.5 times the upper limit of normal value, serum creatinine > 1.5 times the upper limit of normal value); NIHSS Ⅰa ≥2; The expected survival time is less than 3 months; Pregnancy, potential pregnancy, or breastfeeding; Currently participating in other clinical trials during the past 3 months; Those who are judged by researchers to have poor compliance or are not suitable for participating in this study for any other reason.